Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Celiac Disease Market Through 2029?

The market size for celiac disease has witnessed a significant expansion in the past few years. The market is set to surge from $0.71 billion in 2024 to $0.78 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this growth during the historic period include an increased incidence of celiac disease, greater awareness of disorders related to gluten, enhanced research funding towards autoimmune diseases, a spike in food allergies and sensitivities, and a heightened level of health consciousness among consumers.

In the coming years, the celiac disease market is expected to undergo swift growth, reaching a size of $1.15 billion in 2029, with a compound annual growth rate of 10.1%. The growth anticipated in this forecast period can be accredited to a surge in demand for custom-made medicine, improvements in healthcare infrastructure, a growing need for nutritional counseling services, an increase in child diagnosis rates, and emphasis on early childhood screening and prevention. Notable trends within this period are the presence of diagnostic testing, developments in genetic testing technologies, enhanced primary care screening protocols, technological advancements in ELISA and serological testing, and the use of non-invasive diagnostic methods.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp

What Market Forces Are Driving The Celiac Disease Sector In 2025 And Beyond?

The evolution of personalized medicine is anticipated to catalyze the expansion of the celiac disease market in the future. Tailoring healthcare to align with a person’s genetic makeup, surroundings, and lifestyle defines personalized medicine. The surge in demand for this kind of tailored medicine is caused by the advancements in genetic testing, which paves the way for more precise diagnoses and treatments designed to cater to unique patient needs. Personalized medicine boosts celiac disease treatment by providing exact identification of genetic indicators and individual immune responses, which results in more specific and effective treatment strategies for each patient. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the US, reported that the FDA had greenlit 16 personalized therapies in 2023, focusing on rare diseases, which signified an increase from the 6 approved in 2022. Consequently, the evolution of personalized medicine will stimulate the expansion of the celiac disease market.

How Is The Global Celiac Disease Market Categorized By Segments?

The celiac disease market covered in this report is segmented –

1) By Treatment: Infliximab, Larazotide Acetate, Gluten Free Diet, Other Treatments

2) By Route Of Administration: Oral, Parenteral

3) By End Users: Hospitals, Homecare, Other End-Users

Subsegments:

1) By Infliximab: Biosimilar Infliximab, Branded Infliximab, Intravenous Administration, Hospital-Based Usage, Off-Label Use In Refractory Celiac Disease,

2) By Larazotide Acetate: Clinical Trial Phase Products, Oral Capsule Formulation, Adult Celiac Patients, Pediatric Investigational Use, Monotherapy And Combination Therapy

3) By Gluten Free Diet: Packaged Gluten-Free Foods, Gluten-Free Bakery Products, Gluten-Free Snacks, Gluten-Free Nutritional Supplements, Gluten-Free Beverages

4) By Other Treatments: Corticosteroids, Immunosuppressive Drugs, Enzyme Therapies, Monoclonal Antibodies, Probiotics And Microbiome Modulators

What Long-Term Trends Are Likely To Affect The Celiac Disease Market?

Leading firms in the celiac disease market are concentrating on the creation of innovative solutions, such as anti-interleukin-15 (IL-15) antibodies, which help in mitigating tissue injury by controlling excessive immune cell activity. Anti-interleukin-15 (IL-15) antibodies, special types of proteins, impede the functionality of IL-15 cytokine, thus putting a check on the activity of the immune system and inflammation. For instance, in May 2025, the U.S. Food and Drug Administration gave Fast Track status to TEV-53408, an experimental anti-interleukin-15 (IL-15) antibody, launched by Teva Pharmaceutical Industries, a pharmaceutical corporation based in Israel. This exploratory monoclonal antibody, designed especially for individuals with celiac disease who continue to maintain a gluten-free diet, operates by impeding interleukin-15 (IL-15), a substance that sets off the immune reaction leading to intestinal damage in patients with celiac disease. Currently, the safety and efficacy of this treatment option are being examined in a Phase 2a clinical trial.

Which Firms Are Considered Leaders In The Celiac Disease Market Space?

Major companies operating in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report

What Role Do Regional Policies And Investments Play In Celiac Disease Market Expansion?

North America was the largest region in the celiac disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the celiac disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24497&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model